Cargando…
The human anti-IL-1β monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis
INTRODUCTION: IL-1β is a proinflammatory cytokine driving joint inflammation as well as systemic signs of inflammation, such as fever and acute phase protein production. METHODS: ACZ885, a fully human monoclonal antibody that neutralizes the bioactivity of human IL-1β, was generated to study the pot...
Autores principales: | Alten, Rieke, Gram, Hermann, Joosten, Leo A, Berg, Wim B van den, Sieper, Joachim, Wassenberg, Siegfrid, Burmester, Gerd, van Riel, Piet, Diaz-Lorente, Maria, Bruin, Gerardus JM, Woodworth, Thasia G, Rordorf, Christiane, Batard, Yannik, Wright, Andrew M, Jung, Thomas |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2483458/ https://www.ncbi.nlm.nih.gov/pubmed/18534016 http://dx.doi.org/10.1186/ar2438 |
Ejemplares similares
-
The phagocyte specific protein S100A12 as a novel biomarker in Muckle-Wells-Syndrome before and during therapy with Anakinra and Canakinumab (ACZ885)
por: Wittkowski, H, et al.
Publicado: (2008) -
12.4 ACZ885 (canakinumab), a new IL-1 beta blocking monoclonal antibody provides long-lasting remission in children with cryopyrin associated periodic syndrome (CAPS)
por: Kümmerle-Deschner, J, et al.
Publicado: (2008) -
Canakinumab (ACZ885, a fully human IgG1 anti-IL-1β mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS)
por: Kuemmerle-Deschner, Jasmin B, et al.
Publicado: (2011) -
2.2 A phase II trial with canakinumab, a new IL-1beta blocking monoclonal antibody (ACZ885), to evaluate preliminary dosing, safety and efficacy profile in children with systemic Juvenile Idiopathic arthritis (sJIA)
por: Ruperto, N, et al.
Publicado: (2008) -
O056 The effect of acetazolamide and oxygen (ACZ+O2) combination therapy on loop gain and OSA severity
por: Landry, S, et al.
Publicado: (2022)